PMID- 19808198
OWN - NLM
STAT- MEDLINE
DCOM- 20100518
LR  - 20220410
IS  - 1938-0690 (Electronic)
IS  - 1525-7304 (Linking)
VI  - 10
IP  - 5
DP  - 2009 Sep
TI  - MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel 
      tumor-specific approach to therapy.
PG  - 371-4
LID - 10.3816/CLC.2009.n.052 [doi]
AB  - This clinical trial summary provides the background and rationale for a 
      randomized trial, MAGRIT, to investigate the efficacy of MAGE-A3 antigen-specific 
      cancer immunotherapeutic (ASCI) agents in preventing cancer relapse, when 
      administered after tumor resection, in patients with MAGE-A3-positive stages IB, 
      II, and IIIA non-small-cell lung cancer. The study will also evaluate potential 
      side effects of MAGE-A3 ASCIs. The primary endpoint is disease-free survival. The 
      secondary endpoint is prospective validation of the gene signature predictive of 
      benefit from MAGE-A3 ASCI therapy.
FAU - Tyagi, Preeta
AU  - Tyagi P
AD  - GlaxoSmithKline Oncology, Collegeville, PA 19426, USA. preeta.3.tyagi@gsk.com
FAU - Mirakhur, Beloo
AU  - Mirakhur B
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Lung Cancer
JT  - Clinical lung cancer
JID - 100893225
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers)
RN  - 0 (Cancer Vaccines)
RN  - 0 (MAGEA3 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Recombinant Proteins)
SB  - IM
MH  - Antigens, Neoplasm/genetics/*immunology/metabolism
MH  - Biomarkers
MH  - Cancer Vaccines
MH  - Carcinoma, Non-Small-Cell Lung/diagnosis/immunology/pathology/*therapy
MH  - Clinical Trials, Phase III as Topic
MH  - Disease-Free Survival
MH  - Gene Expression Profiling
MH  - Humans
MH  - *Immunotherapy, Active/adverse effects
MH  - Lung Neoplasms/diagnosis/immunology/pathology/*therapy
MH  - Neoplasm Proteins/genetics/*immunology/metabolism
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Randomized Controlled Trials as Topic
MH  - Recombinant Proteins/genetics/*immunology/metabolism
MH  - Secondary Prevention
MH  - Treatment Outcome
EDAT- 2009/10/08 06:00
MHDA- 2010/05/19 06:00
CRDT- 2009/10/08 06:00
PHST- 2009/10/08 06:00 [entrez]
PHST- 2009/10/08 06:00 [pubmed]
PHST- 2010/05/19 06:00 [medline]
AID - S1525-7304(11)70445-4 [pii]
AID - 10.3816/CLC.2009.n.052 [doi]
PST - ppublish
SO  - Clin Lung Cancer. 2009 Sep;10(5):371-4. doi: 10.3816/CLC.2009.n.052.